EUDA Health Holdings Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Alfred Lim
- Full Time Employees
- 123
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 60 Kaki Bukit Place Singapore CE Singapore 415979
- IPO Date
- Dec 14, 2021
- CIK
- 0001847846
- Website
- eudahealth.com
- Similar Companies
- Business
- EUDA Health Holdings Limited (EUDA) is a Singapore-based health technology company that operates a digital healthcare ecosystem focused on non-invasive, preventive, and holistic wellness solutions primarily in Southeast Asia, including Singapore, Malaysia, and China. The company provides a proprietary AI-powered platform offering e-triage, teleconsultations with general practitioners, digital medical certificates and prescriptions, urgent care services, specialist referrals, mental health support, physiotherapy, health screenings, and medication delivery through its MyEUDA app; lifestyle and wellness products such as bioenergy cabins, Helixe supplements, Yoroyal holistic wellness items via direct selling, e-commerce, and retail channels, wellness therapies, and membership programs; health plans integrating insurers and providers; and property management services for shopping malls, office buildings, residential apartments, and condominiums. Founded in 2019 by Dr. Kelvin Chen and headquartered at 60 Kaki Bukit Place #03-01, Eunos Techpark, Singapore, EUDA targets individual consumers, corporate clients, and employees seeking affordable, accessible care from wellness prevention to post-treatment aftercare. Recent developments include the May 2024 acquisition of CK Health Plus Sdn Bhd for US$15 million in shares to expand direct-selling of holistic wellness products and license bioenergy cabins to spas and salons; a December 2024 announcement of a potential joint venture with Guangdong Cell Biotech for stem cell therapies and regenerative medicine across Asia; and an August 2025 convertible note issuance completed in November 2025 to enhance liquidity amid ongoing strategic growth in the region's US$740 billion healthcare market.
Company News
EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore
EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products
EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products
EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies
EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies
Phreesia (NYSE:PHR) & EUDA Health (NASDAQ:EUDA) Head-To-Head Review
EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency
EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency
EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities
Contrasting EUDA Health (NASDAQ:EUDA) and Outset Medical (NASDAQ:OM)
EUDA Announces Reverse Stock Split of its Ordinary Shares
EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant
Comparing Hinge Health (NYSE:HNGE) and EUDA Health (NASDAQ:EUDA)
EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform
EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement
EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital